Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that finasteride 1 mg improved hair growth in 85.7% of Korean men with androgenetic alopecia over five years, with varying effectiveness depending on the type of hair loss.

This systematic review reported that post-COVID-19 sequelae most commonly affect the lungs, followed by skin and psychiatric symptoms, with higher incidence in women and those with severe COVID-19 or comorbid conditions.

This study found that approximately 85% of adults with severe alopecia areata who responded to baricitinib at 52 weeks maintained their improvement over a span of four years.

This study found that many young women with breast cancer experience a poor quality of life over time, especially regarding sexual health, future perspective, and hair loss.

This study found that both combined therapy with goserelin and oral contraceptives, and oral contraceptives alone, significantly reduced hair diameter in severe hirsutism without a significant difference between treatments.

In this South Korean retrospective study, dutasteride improved hair growth more effectively than finasteride in men with androgenic alopecia, and had a similar or possibly lower rate of adverse events, suggesting it as a viable treatment option.

This article discusses the potential health risks associated with long-term use of finasteride and dutasteride for prostate and hair loss treatments, suggesting risks may include non-alcoholic fatty liver disease, insulin resistance, type 2 diabetes, and other metabolic issues.

This study proposed and tested an Ensemble Pre-Learned Deep Learning and Optimized Long Short-Term Memory (EPL-OLSTM) model for classifying Alopecia Areata, achieving a 93.1% accuracy in differentiating healthy from varying severity levels of AA scalp hair using specific datasets.

This study suggests that long-term treatment with valproate, acetylcarnitine, folic acid, and vitamin B12 may benefit children with SMA types II and III by improving muscle strength and function without significant adverse effects.

This study found that tenofovir alafenamide fumarate (TAF) is an effective and safer alternative to tenofovir disoproxil fumarate (TDF) for chronic hepatitis B, with fewer long-term side effects like nephrotoxicity and decreased bone density.

This study of FAERS data suggests that finasteride, particularly at the 1 mg dosage, is associated with a wide range of adverse effects not previously established in long-term studies, especially among younger men.

This report describes a study of estuarine bed-sediment quality in New Jersey and New York post-Hurricane Sandy, focusing on contamination extent and potential long-term impacts, with no new findings included.

This study found a significant association between finasteride use and increased risk of memory impairment, highlighting the need for risk communication and routine cognitive monitoring for long-term users.

This Cochrane Review protocol aims to evaluate the effectiveness and safety of various treatments for alopecia areata through a network meta-analysis, but no specific study findings are reported yet.

This study found that newborn hair caffeine content reflects maternal caffeine intake during the third trimester, providing a potential method for assessing fetal caffeine exposure.

This narrative review found that while exosome-based therapies hold regenerative potential for skin rejuvenation, wound healing, and hair restoration, significant challenges, including variability in manufacturing and lack of regulatory approval, necessitate careful integration into dermatology practice, emphasizing the importance of patient safety and regulatory understanding.

This editorial examines how GLP-1 receptor agonists, providing significant weight loss and cardiovascular benefits, can be integrated into a comprehensive obesity treatment alongside diet and lifestyle changes, but highlights the need for further guidance on their real-world application and multidisciplinary care.

This study found that SARS-CoV-2 infection was associated with an increased long-term risk of developing alopecia areata in a large bi-national cohort from South Korea and Japan.

This document outlines recommendations from an international panel on testosterone therapy for aging men with late-onset hypogonadism, emphasizing the need for careful assessment and monitoring due to limited long-term safety data.

This paper reviews existing and emerging therapies for alopecia areata, describing the impact of targeted treatments in this field, and introduces a global network of disease registers to study the long-term safety and effectiveness of these new options.

This narrative review discusses how new targeted therapies, like biologics and small molecules, are transforming alopecia areata treatment and highlights the establishment of the GRASS-UK/GRASS-International network to investigate the long-term safety and effectiveness of these new treatments.

This study reviews both traditional and innovative therapies for alopecia areata, focusing on the potential benefits and challenges of newer targeted treatments while introducing GRASS-UK/GRASS-International as networks aimed at assessing the long-term safety and effectiveness of these therapies worldwide.

This study found that many COVID-19 survivors experience persistent psychological symptoms, hair loss, and other health issues, highlighting the need for further long-term research on these prolonged effects.

According to this study, nearly one-third of the participants experienced Long COVID, highlighting ongoing concerns about the disease's long-term implications despite the pandemic being under control.

This study reports that hedgehog pathway inhibitors, sonidegib and vismodegib, showed distinct adverse event patterns in real-world data, suggesting the need for further research to confirm these findings.

This dataset provides supplemental material for a study on long-term particulate matter exposure and androgenetic alopecia risk, including additional exposure data and sensitivity analyses, but reports no new clinical results.

This study analyzed pexidartinib-associated adverse events from FDA data and reported common events such as hepatic issues and systemic reactions. It highlighted sex-specific susceptibilities and reinforced the need for risk mitigation and long-term monitoring in tenosynovial giant cell tumor management.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This dataset provides additional exposure data and comprehensive analyses for a study on the long-term effects of particulate matter on androgenetic alopecia, but it presents no new findings.

This article discusses the need for long-term studies on pathways for children and adolescents in gender services and reports no new findings; the authors call for data on psychological care.